Glycosaminoglycan silencing by engineered CXCL12 variants.

@article{Gschwandtner2015GlycosaminoglycanSB,
  title={Glycosaminoglycan silencing by engineered CXCL12 variants.},
  author={Martha Gschwandtner and Martin U Trinker and Bianca Hecher and Tiziana Adage and Simi Ali and Andreas J. Kungl},
  journal={FEBS letters},
  year={2015},
  volume={589 19 Pt B},
  pages={2819-24}
}
We have engineered GPCR (G protein-coupled receptor) knock-out and high GAG-binding affinity into CXCL12α to inhibit CXCL12α-induced cell migration. Compared to wtCXCL12, the mutant CXCL12α (Δ8 L29K V39K) exhibited a 5.6-fold and a 2.2-fold affinity increase for heparin and heparan sulfate, respectively. From NaCl-based heparin displacement chromatography we concluded that more amino acid replacements would lead to altered GAG (glycosaminoglycan) ligand specificity. GAG silencing by this mutant… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
2 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Similar Papers

Loading similar papers…